128,006 Shares in Maze Therapeutics, Inc. $MAZE Purchased by Walleye Capital LLC

Walleye Capital LLC purchased a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the 2nd quarter, Holdings Channel.com reports. The fund purchased 128,006 shares of the company’s stock, valued at approximately $3,820,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Mass General Brigham Inc purchased a new stake in shares of Maze Therapeutics in the fourth quarter worth approximately $9,943,000. Boothbay Fund Management LLC boosted its holdings in Maze Therapeutics by 16.3% during the 4th quarter. Boothbay Fund Management LLC now owns 409,372 shares of the company’s stock valued at $16,960,000 after acquiring an additional 57,497 shares during the period. Spruce Street Capital LP bought a new position in Maze Therapeutics in the 1st quarter valued at $5,970,000. Eventide Asset Management LLC bought a new position in Maze Therapeutics in the 4th quarter valued at $13,425,000. Finally, Exome Asset Management LLC purchased a new stake in Maze Therapeutics in the first quarter worth $2,642,000.

Analyst Upgrades and Downgrades

MAZE has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics News Summary

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Insider Transactions at Maze Therapeutics

In related news, CMO Harold Bernstein sold 16,142 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total value of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares of the company’s stock, valued at $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the sale, the chief executive officer directly owned 23,337 shares in the company, valued at $699,643.26. This trade represents a 59.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 140,674 shares of company stock valued at $3,904,707. Company insiders own 5.30% of the company’s stock.

Maze Therapeutics Price Performance

MAZE opened at $27.18 on Friday. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. The company has a current ratio of 18.31, a quick ratio of 17.88 and a debt-to-equity ratio of 0.09. Maze Therapeutics, Inc. has a 12-month low of $12.81 and a 12-month high of $53.65. The business’s fifty day simple moving average is $27.79 and its 200-day simple moving average is $33.03.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.76). On average, equities research analysts anticipate that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current fiscal year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.